#USA #Minneapolis #Medical Devices #VentureMed Group #Bruce Fiedler

VentureMed Group Welcomes New Leadership

VentureMed Group, Inc., a prominent player in the medical device sector, has announced the appointment of Bruce Fiedler as the Chief Financial Officer (CFO). Based in Minneapolis, the company specializes in innovative technologies for vessel preparation and access management, particularly focused on treating arteriovenous fistulas, grafts, and peripheral vascular disease. Fiedler's extensive background in finance positions him as an asset in steering the company's financial operations.

Fiedler joins VentureMed Group with a wealth of experience, having previously served as Vice President of Finance and Global Controller for the Neuromodulation Division at Boston Scientific. His leadership there encompassed broad financial planning and management responsibilities for a substantial global business unit, showcasing his capability in high-stakes financial environments. With a robust reputation earned through his career, Fiedler is known for his operational excellence and a commitment to financial discipline—a combination that aligns well with VentureMed's ambitions.

As CFO, Fiedler will take control over all financial operations of VentureMed Group, which include strategic planning, financial reporting, and investor relations. His role is crucial as the company pushes forward in delivering transformative vascular solutions to clinicians and patients worldwide. This leadership transition comes at a pivotal time as VentureMed Group aims to scale its operations and drive growth.

Denis Harrington, the President and CEO of VentureMed Group, expressed enthusiasm about Fiedler's appointment, stating, "We are thrilled to welcome Bruce into our leadership team. His financial acumen and industry experience are vital as we navigate the next phase of our growth. Bruce’s strategic insights will undoubtedly bolster our financial foundation and contribute to long-term value creation."

In his own words, Fiedler communicated his excitement about joining the organization at this crucial juncture. "The mission of addressing unmet clinical needs through remarkable vascular solutions is inspiring, and I am eager to collaborate with the team to foster growth and significantly impact patients and physicians alike," he stated.

About VentureMed Group

VentureMed Group is a trailblazing, privately held medical device firm dedicated to enhancing endovascular solutions for arteriovenous (AV) access and peripheral vascular disease interventions. Central to its offerings is the FLEX Vessel Prep™ System, an FDA 510(k)-cleared and CE Mark-approved device. This technology optimizes vessel preparation using innovative Kinetic Endovascular Micro-incision Creation (KEMIC) techniques—a method that stands out compared to traditional balloon-based approaches, which tend to apply static pressure. By utilizing controlled motion and dynamic vessel apposition, the KEMIC technology works to create precise micro-incisions, aiming for more effective vascular interventions.

For those interested in learning more about the advancements and products offered by VentureMed Group, additional information can be found on their website at www.VentureMedgroup.com.

This leadership change and Fiedler's vast experience could signal a period of significant development and innovation for VentureMed Group as they continue to enhance their impact on the medical device industry.